Exicure, Inc. (XCUR)
NASDAQ: XCUR · Real-Time Price · USD
3.710
+0.059 (1.62%)
At close: Nov 14, 2025, 4:00 PM EST
3.700
-0.010 (-0.27%)
After-hours: Nov 14, 2025, 4:10 PM EST
Exicure Revenue
In the year 2024, Exicure had annual revenue of $500.00K.
Revenue (ttm)
$500.00K
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
7
Market Cap
23.65M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 500.00K | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 28.83M | 29.31M | -6,068.12% |
| Dec 31, 2021 | -483.00K | -17.10M | -102.91% |
| Dec 31, 2020 | 16.61M | 15.32M | 1,181.87% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
XCUR News
- 8 days ago - Exicure, Inc. Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 12 days ago - New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual Meeting - GlobeNewsWire
- 24 days ago - Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights - Business Wire
- 5 weeks ago - Exicure Highlights Recent Achievements and Near-term Strategic Priorities - GlobeNewsWire
- 3 months ago - Exicure, Inc. Reports Second Quarter 2025 Financial Results - Business Wire
- 3 months ago - Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements - Business Wire
- 3 months ago - Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant - Business Wire
- 5 months ago - Exicure, Inc. Reports First Quarter 2025 Financial Results - Business Wire